NCT03758976 Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec)
| NCT ID | NCT03758976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lund University Hospital |
| Condition | Metastatic Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2019-01-21 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2019-01-21 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective multicenter observational study to assess molecular drivers of metastatic breast cancer and disease evolution upon therapeutic pressure. The main aim is to develop and validate prognostic, predictive and pathogenic markers in clinically well-characterized population-based material of breast cancer tumors and the corresponding normal tissue.These data will be used to characterize recurrent breast cancer on a molecular level, study tumor evolution, develop biomarkers of response/resistance to targeted therapy in the metastatic setting, enroll patients on targeted treatment clinical studies and to elucidate mechanisms of resistance to therapy.
Eligibility Criteria
Inclusion Criteria: 1. Patients with pathologically confirmed advanced breast cancer (ABC), including locally advanced inoperable disease and stage IV disease. 2. Age \> 18 years. 3. Performance status according to Eastern Cooperative Oncology Group (ECOG) ≤ 2. 4. ABC must be radiologically or clinically assessable, by means of at least one of the following techniques: clinical examination, computerized tomography (CT-scan), magnetic resonance imaging (MRI), bone scintigraphy or positron emission tomography (PET). 5. Patients must have a radiological evaluation done maximum 6 weeks prior to inclusion. 6. Signed informed consent according to ICH/GCP, and national/local regulations. Exclusion Criteria: Untreated psychiatric disorders that will impair the patient's ability to comply with study treatment or protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03758976 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03758976 currently recruiting?
Yes, NCT03758976 is actively recruiting participants. Contact the research team at karolina.holm@med.lu.se for enrollment information.
Where is the NCT03758976 trial being conducted?
This trial is being conducted at Lund, Sweden, Lund, Sweden.
Who is sponsoring the NCT03758976 clinical trial?
NCT03758976 is sponsored by Lund University Hospital. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.